2-furoyl-LIGRLO-amide: a potent and selective proteinase-activated receptor 2 agonist.
about
Beta-arrestin-dependent regulation of the cofilin pathway downstream of protease-activated receptor-2Characterization and Functions of Protease-Activated Receptor 2 in Obesity, Diabetes, and Metabolic Syndrome: A Systematic ReviewProtease-activated receptor 2 signalling promotes dendritic cell antigen transport and T-cell activation in vivoDevelopment and evaluation of small peptidomimetic ligands to protease-activated receptor-2 (PAR2) through the use of lipid tetheringThe Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptorsbeta-Arrestins scaffold cofilin with chronophin to direct localized actin filament severing and membrane protrusions downstream of protease-activated receptor-2.Alternaria alternata serine proteases induce lung inflammation and airway epithelial cell activation via PAR2.Beta-arrestin inhibits CAMKKbeta-dependent AMPK activation downstream of protease-activated-receptor-2.Profiling gene expression induced by protease-activated receptor 2 (PAR2) activation in human kidney cellsProteinase-activated receptor 2-mediated calcium signaling in hepatocellular carcinoma cells.Role for β-arrestin in mediating paradoxical β2AR and PAR2 signaling in asthma.Activation of protease activated receptor 2 by exogenous agonist exacerbates early radiation injury in rat intestineProtection of protease-activated receptor 2 mediated vasodilatation against angiotensin II-induced vascular dysfunction in miceApical and basolateral pools of proteinase-activated receptor-2 direct distinct signaling events in the intestinal epithelium.PAR2 Modulators Derived from GB88.The protease-activated receptor-2-specific agonists 2-aminothiazol-4-yl-LIGRL-NH2 and 6-aminonicotinyl-LIGRL-NH2 stimulate multiple signaling pathways to induce physiological responses in vitro and in vivo2-Furoyl-LIGRL-NH2, a potent agonist for proteinase-activated receptor-2, as a gastric mucosal cytoprotective agent in mice.Perivascular adipose tissue-derived relaxing factors: release by peptide agonists via proteinase-activated receptor-2 (PAR2) and non-PAR2 mechanisms.The novel PAR2 ligand C391 blocks multiple PAR2 signalling pathways in vitro and in vivo.β-Arrestin-2 mediates the proinflammatory effects of proteinase-activated receptor-2 in the airway.Protease-activated receptor 2 (PAR2) protein and transient receptor potential vanilloid 4 (TRPV4) protein coupling is required for sustained inflammatory signaling.Development of highly potent protease-activated receptor 2 agonists via synthetic lipid tethering.Proteinase-activated receptor 2 activation promotes an anti-inflammatory and alternatively activated phenotype in LPS-stimulated murine macrophages.Proteinase-activated receptor 2 (PAR2) in hepatic stellate cells - evidence for a role in hepatocellular carcinoma growth in vivoRole of mast cells and protease-activated receptor-2 in cyclooxygenase-2 expression in urothelial cells.PAR2 regulates regeneration, transdifferentiation, and deathProteinase-activated receptors 1 and 2 and the regulation of porcine coronary artery contractility: a role for distinct tyrosine kinase pathways.Biased signaling of protease-activated receptors.Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Bronchoprotection and bronchorelaxation in asthma: New targets, and new ways to target the old ones.Proteinases, Their Extracellular Targets, and Inflammatory Signaling.Age-related changes to vascular protease-activated receptor 2 in metabolic syndrome: a relationship between oxidative stress, receptor expression, and endothelium-dependent vasodilation.Potent agonists of the protease activated receptor 2 (PAR2).Met receptor tyrosine kinase transactivation is involved in proteinase-activated receptor-2-mediated hepatocellular carcinoma cell invasion.Protease-activated receptor-2 stimulates intestinal epithelial chloride transport through activation of PLC and selective PKC isoforms.EGF receptor transactivation and MAP kinase mediate proteinase-activated receptor-2-induced chloride secretion in intestinal epithelial cells.Proteinase-activated receptor-2 activating peptides: distinct canine coronary artery receptor systems.Differential effects of beta-arrestins on the internalization, desensitization and ERK1/2 activation downstream of protease activated receptor-2.Binding of a highly potent protease-activated receptor-2 (PAR2) activating peptide, [3H]2-furoyl-LIGRL-NH2, to human PAR2.Constitutive protease-activated receptor-2-mediated migration of MDA MB-231 breast cancer cells requires both beta-arrestin-1 and -2.
P2860
Q24305533-D550BD4E-3A45-41E8-B088-1D41B146F63FQ26752383-86FB7E7F-BFE1-4567-B30D-0A0AA525DAC7Q28511351-776BD9FF-D369-4ADE-BC26-0DCAA1A572FCQ28539692-EE41CF74-21D4-4A9D-A984-F4B6E8592401Q30486707-0B0138D7-E932-4892-B3BD-A74A172F0B33Q30494324-A05993E9-E27C-4F93-AA63-5CF5CF23B9D3Q30499470-3757588B-F02B-4F53-9941-BC04EAE37285Q33698673-D24A98AD-C516-4385-833B-FD7280076129Q33745121-DD35D3D4-9CCC-41CC-81B1-3BB63E60F52DQ33761497-8760F780-BE02-40BE-9325-2DB559E8CEDFQ33975010-21A0C4D2-F175-4E47-9B5C-5F4F5AFD4EE5Q33984148-F1B78160-D277-4974-9A82-4CA3ED3DC684Q34034013-FD410107-72C7-4102-AD31-9D60BC30725FQ34501717-13A9A755-A48B-4592-94D8-FF800BA40B7BQ34547663-4394E09A-182A-461D-A290-FEE2A88838E0Q34998283-01F04016-D995-41A1-9398-7C1C68975DE8Q35048527-59B6B0F9-00E7-46BD-B00F-668C972EA965Q35635977-C4C04CCE-AD18-4EFC-B589-043FEF6455B8Q36036250-56796308-77D1-4727-9EAE-30FAF4A387ACQ36339904-39D1FAD6-C6FC-446B-9981-325DB1510CDFQ36635888-BDC35533-C7BB-4A46-9C5F-B8AC560692FEQ36710897-6E32D2B8-0B1F-42F5-850E-0971EFE89C4FQ37047991-A94D93C0-E80C-43B7-87C8-96721E5D73F9Q37138893-7AD1F5C2-1001-4870-9A76-53F41947FB81Q37391866-636A88B7-A0BC-4D19-9249-CB1BE8445246Q37603262-9891FE42-1F4A-4CAE-A548-AFB35166E388Q37719424-D2CA282C-7643-47E0-957D-58B0FA1B8300Q38214613-2281EAF9-21B7-4EA5-AC33-A9A2A921F790Q38758445-14EADD3D-11E4-4F87-A2A2-C4F6261D8EB3Q38817408-AF51B830-6317-4482-8934-7631C5313C24Q38966192-51A772E6-7268-4315-9184-E8F2B70B5247Q39012523-4A8C9700-7287-41C3-9B9F-93B401FCC31FQ39597862-4BF06383-8CBD-417E-B41E-E41062DA5BF9Q39834780-4854EA0F-8F1F-49E6-9FE6-E06C8F72AEE4Q39862177-96AF27F8-00EE-4719-A5E1-377350838AFFQ40046447-12F900B2-578A-48BB-AB31-C5E1C02FCAF1Q40086036-A69FCCF1-F9B2-468A-AB4B-21DF27BB7A83Q40144013-28598342-77E0-453A-AA28-AB5EC0F153D6Q40447234-E283D36F-E470-4EA1-BC8D-9764328A6255Q40503317-049824DF-8DE1-4B04-8E41-369F1A965930
P2860
2-furoyl-LIGRLO-amide: a potent and selective proteinase-activated receptor 2 agonist.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
2-furoyl-LIGRLO-amide: a potent and selective proteinase-activated receptor 2 agonist.
@en
2-furoyl-LIGRLO-amide: a potent and selective proteinase-activated receptor 2 agonist.
@nl
type
label
2-furoyl-LIGRLO-amide: a potent and selective proteinase-activated receptor 2 agonist.
@en
2-furoyl-LIGRLO-amide: a potent and selective proteinase-activated receptor 2 agonist.
@nl
prefLabel
2-furoyl-LIGRLO-amide: a potent and selective proteinase-activated receptor 2 agonist.
@en
2-furoyl-LIGRLO-amide: a potent and selective proteinase-activated receptor 2 agonist.
@nl
P2093
P356
P1476
2-furoyl-LIGRLO-amide: a potent and selective proteinase-activated receptor 2 agonist.
@en
P2093
Kimberly Sun
Mahmoud Saifeddine
Morley D Hollenberg
P304
P356
10.1124/JPET.103.064584
P407
P577
2004-02-19T00:00:00Z